IP Library Granted Patent US 8,772,469
Granted Patent B2
US 8,772,469 · App. 10/193,747 · Granted Jul 8, 2014

Synthetic double-stranded oligonucleotides for specific inhibition of gene expression

Inventors: Eugen Uhlmann (Glashütten, DE); Jochen Huber (Maxdorf, DE); Niki Gunkel (Heidelberg, DE); Sandra Neumann (Offenbach, DE)
Assignee: Sanofi-Aventis Deutschland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,469
App. No.
10/193,747
Granted
Jul 8, 2014
Kind
B2
Abstract

The present invention relates to oligonucleotide derivatives which are at least partly double-stranded and which have a 2′5′-linked oligonucleotide residue on at least one 3′ end and to the use thereof for specific inhibition of gene expression.

Claims (36)

1. A double-stranded RNA oligonucleotide of Formula I

5′-(U)vX-(N)x-(W)-3′

3′-(Z)n-(N′)y-5′  Formula I

wherein

N and N′ are naturally occurring nucleotides bound by 3′,5′ internucleotide bonds, wherein a portion of the oligonucleotide is double-stranded between (N)x and (N′)y, and wherein the nucleotide strand (N)x, is sufficiently complementary to a target RNA to hybridize thereto and inhibit its expression through RNA interference, and wherein the nucleotide strand (N′)y is at least partially homologous to the target RNA, and wherein

N is selected from the group consisting of adenine (A), cytosine (C), guanine (G), and uracil (U);

x is independently 15-25;

y is independently 15-25;

n is independently 4 to 6;

v is independently 1 to 20, whereas: when v=1, X is selected from the group consisting of A, C, and G, and when v=2 to 20, X is absent;

W is selected from the group consisting of U2-20, UA, UC, and UG, or is absent; and Z is A; nucleotides of W being linked via a 3′,5′ internucleotide bond, and

wherein at least two nucleotides of Z are linked via a 2′,5′ internucleotide bond and are present in a single-stranded form that does not base pair with the target gene or with the RNA homologous thereto, thereby forming a 2′,5′ linked oligonucleotide residue on the 3′ end of the nucleotide strand (N′)y and wherein the internucleotide bonds in the double-stranded oligonucleotide are 3′,5′ or 2′,5′ internucleotide bonds.

2. The double-stranded RNA of claim 1 , wherein v is 2 to 10.

3. The double-stranded RNA of claim 2 , wherein v is 2 to 6.

4. The double-stranded RNA of claim 1 , wherein U 2-20 is U 2-10 .

5. The double-stranded RNA of claim 4 , wherein U 2-20 is U 2-6 .

6. The double-stranded RNA of claim 1 , wherein x is 16 to 23.

7. The double-stranded RNA of claim 6 , wherein x is 19 to 21.

8. The double-stranded RNA of claim 1 , wherein Z is adenosine or 3′-deoxyadenosine.

9. The double-stranded RNA of claim 1 , in which one or more natural phosphodiester bonds have been replaced by unnatural internucleotide bonds that stabilize against nuclease degradation.

10. The double-stranded RNA of claim 9 , in which one or more natural phosphodiester bonds have been replaced by phosphorothioate bonds.

11. The double-stranded RNA of claim 10 , in which a plurality of natural phosphodiester bonds have been replaced by phosphorothioate bonds, with said replacements being located on the 5′ or 3′ ends of the oligonucleotide, and on internal pyrimidine nucleotides of the oligonucleotide.

12. The double-stranded RNA of claim 1 , wherein one of nucleotide strands (N) x or (N′) y , is between 23 and 65 nucleotides in length and the other of the nucleotide strands is between 23 and 31 nucleotides in length.

13. The double stranded RNA of claim 1 , wherein the double stranded RNA comprises one or more 2′ O-methylribonucleotides.

14. The double stranded RNA of claim 1 , wherein the double stranded RNA comprises one or more 2′ fluoro-2′-deoxyribonucleotides.

15. The double stranded RNA of claim 1 , wherein the double stranded RNA comprises one or more locked nucleic acids (LNA).

16. The double stranded RNA of claim 1 , wherein the double stranded RNA further comprises a linker that links the two RNA strands.

17. The double stranded RNA of claim 16 , wherein the linker is a nucleotide linker.

18. The double stranded RNA of claim 16 , wherein the nucleotide linker comprises thymidine.

19. The double stranded RNA of claim 16 , wherein the nucleotide linker comprises 4-20 nucleotide residues.

20. The double stranded RNA of claim 19 , wherein the 4-20 nucleotide residues comprise one or more thymidines.

21. The double stranded RNA of claim 19 , wherein the 4-20 nucleotide residues are thymidines.

22. The double stranded RNA of claim 16 , wherein the nucleotide linker comprises 4-5 nucleotide residues.

23. The double stranded RNA of claim 22 , wherein the 4-5 nucleotide residues comprise one or more thymidines.

24. The double stranded RNA of claim 23 , wherein the 4-5 nucleotide residues are thymidines.

25. The double stranded RNA of claim 16 , wherein the linker is a non-nucleotide linker.

Assignments (3)
CHANGE OF NAME Recorded Dec 3, 2008
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 021918/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2008
From: UHLMANN, EUGEN; HUBER, JOCHEN; GUNKEL, NIKI; NEUMANN, SANDRA
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 021851/0844 →
CHANGE OF NAME Recorded Nov 18, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016793/0789 →
Priority Claims (1)
DE 101 33 858 · Jul 12, 2001 · national
Continuity (1)
Related Publication 20030139585A1 · Jul 24, 2003